Loading...
Background and Objective
A diagnosis of hereditary hemorrhagic telangiectasia (HHT) is often delayed, yet suspicion is raised when patients present with complications, (e.g., acute or chronic bleeding, shunting) from vascular malformations (VMs) of the skin, mucous membranes, brain, lungs, or liver. Now, an international panel provides expert guidance on these key clinical complications and addresses unique concerns for pediatric and obstetrical patients.
Key Recommendations
Moisturizing topical therapy is suggested as a first-line treatment for HHT-associated epistaxis, followed by oral tranexamic acid and ablative therapies as second-line options; antiangiogenic agents are offered should the above measures fail to control epistaxis.
In pati…